Related Experiment Video
Updated: Mar 25, 2026

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
Eco-evolution of cancer resistance
1Tufts University School of Medicine, Boston, MA 20111, USA. Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA 02111, USA. Floating Hospital for Children at Tufts Medical Center, Boston, MA 02111, USA. glakkaklement@tuftsmedicalcenter.org.
Abstract:
For the past 60 years, the goal of conventional cancer therapies has been the eradication of every cancer cell. To this end, patients are subjected to the highest possible doses of radiation and chemotherapy as well as radical surgeries. In the rare case in which eradication was possible, clinicians achieved long-term control of the disease. For the most part, however, upfront eradication is not possible, and despite intensive and very toxic therapies, the patient dies of the disease or of complications of therapy. As our understanding about the role of tumor microenvironment in tumor progression and drug resistance improves, we are realizing that the paradigm of killing all cancer cells may be flawed.
Related Concept Videos
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Cancers Originate from Somatic Mutations in a Single Cell

